High levels of CCR2, CCR5, and CXCR4 at 1 week further supported active DC trafficking toward lymphoid tissues and tumor sites, while increased IL-10 may reflect early regulatory feedback within an immunostimulatory context (Table S6). The gene discussed is CCR2; the disease is neoplasm.